HbA1c: an independent risk factor for dysthyroid optic neuropathy.
HbA1c
diabetes mellitus
dysthyroid optic neuropathy
risk factor
thyroid-associated ophthalmopathy
Journal
Frontiers in endocrinology
ISSN: 1664-2392
Titre abrégé: Front Endocrinol (Lausanne)
Pays: Switzerland
ID NLM: 101555782
Informations de publication
Date de publication:
2023
2023
Historique:
received:
01
07
2023
accepted:
07
09
2023
medline:
27
10
2023
pubmed:
26
10
2023
entrez:
26
10
2023
Statut:
epublish
Résumé
We aimed to explore the frequencies of islet β-cell autoantibodies and insulin resistance (IR) in thyroid-associated ophthalmopathy (TAO) and identify specific diabetes mellitus (DM) indicators as early predictors for dysthyroid optic neuropathy (DON). Ninety-eight TAO patients (57 DON and 41 non-DON patients) and 48 healthy control (HC) participants were recruited for this prospective cross-sectional study. Serum thyroxine, serum thyroid autoantibodies, serum humoral immune markers against islet β-cell, fasting plasma glucose (FPG), fasting serum insulin (FINS), fasting c-peptide (FCP), and glycosylated hemoglobin A1 (HbA1c) were measured. Logistic regression analysis was used to evaluate the correlation of patients' age, body mass index (BMI), FPG, HbA1c, and related indexes of islet β-cell function to the occurrence of DON. The DON group had higher FPG (P<0.001, 0.016) and HbA1c (P<0.0001, P<0.001) levels than the HC and non-DON groups. The homeostasis model assessment (HOMA)-IR level was the highest in the DON group (HC 2.15 ± 0.89, non-DON 2.41 ± 1.24, and DON 2.82 ± 2.65), while the HOMA-β level was the lowest (HC 101.8 ± 44.75%, non-DON 102.9 ± 54.61%, and DON 88.29 ± 52.75%), with no significant differences (P=1, P>0.05). On univariate analysis, age (P=0.006), BMI (P=0.022), history of steroid use (P=0.014), FPG (P=0.013), and HbA1c (P=0.001) levels were significantly associated with the presence/absence of DON. In addition, after adjusting for potential confounds, the HbA1c level was an independent factor associated with DON (P=0.009, OR=4.012). HbA1c is an independent risk factor for DON. Given the interconnected link between thyroid dysfunction and DM, the use of HbA1c as a potential biomarker for DON warrants further investigation.
Sections du résumé
Background
We aimed to explore the frequencies of islet β-cell autoantibodies and insulin resistance (IR) in thyroid-associated ophthalmopathy (TAO) and identify specific diabetes mellitus (DM) indicators as early predictors for dysthyroid optic neuropathy (DON).
Methods
Ninety-eight TAO patients (57 DON and 41 non-DON patients) and 48 healthy control (HC) participants were recruited for this prospective cross-sectional study. Serum thyroxine, serum thyroid autoantibodies, serum humoral immune markers against islet β-cell, fasting plasma glucose (FPG), fasting serum insulin (FINS), fasting c-peptide (FCP), and glycosylated hemoglobin A1 (HbA1c) were measured. Logistic regression analysis was used to evaluate the correlation of patients' age, body mass index (BMI), FPG, HbA1c, and related indexes of islet β-cell function to the occurrence of DON.
Results
The DON group had higher FPG (P<0.001, 0.016) and HbA1c (P<0.0001, P<0.001) levels than the HC and non-DON groups. The homeostasis model assessment (HOMA)-IR level was the highest in the DON group (HC 2.15 ± 0.89, non-DON 2.41 ± 1.24, and DON 2.82 ± 2.65), while the HOMA-β level was the lowest (HC 101.8 ± 44.75%, non-DON 102.9 ± 54.61%, and DON 88.29 ± 52.75%), with no significant differences (P=1, P>0.05). On univariate analysis, age (P=0.006), BMI (P=0.022), history of steroid use (P=0.014), FPG (P=0.013), and HbA1c (P=0.001) levels were significantly associated with the presence/absence of DON. In addition, after adjusting for potential confounds, the HbA1c level was an independent factor associated with DON (P=0.009, OR=4.012).
Conclusions
HbA1c is an independent risk factor for DON. Given the interconnected link between thyroid dysfunction and DM, the use of HbA1c as a potential biomarker for DON warrants further investigation.
Identifiants
pubmed: 37881496
doi: 10.3389/fendo.2023.1251209
pmc: PMC10597662
doi:
Substances chimiques
Glycated Hemoglobin
0
Autoantibodies
0
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Langues
eng
Sous-ensembles de citation
IM
Pagination
1251209Informations de copyright
Copyright © 2023 Wang, Ye, Chen, Yang, Zhang, Xiao and Yang.
Déclaration de conflit d'intérêts
The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.
Références
Endocr Rev. 2019 Feb 1;40(1):236-267
pubmed: 30215690
Eur J Endocrinol. 1997 Nov;137(5):503-10
pubmed: 9405030
Exp Clin Endocrinol Diabetes. 2006 Sep;114(8):412-6
pubmed: 17039421
Trends Endocrinol Metab. 2005 May-Jun;16(4):190-7
pubmed: 15860416
Invest Ophthalmol Vis Sci. 2019 May 1;60(6):1863-1869
pubmed: 31042792
Int J Endocrinol Metab. 2021 Jan 19;19(1):e105751
pubmed: 33815517
Am J Ophthalmol. 1995 Jun;119(6):792-5
pubmed: 7785696
J Clin Endocrinol Metab. 2000 Mar;85(3):1194-9
pubmed: 10720061
JAMA. 2013 Jun 19;309(23):2473-9
pubmed: 23780460
Diabetes. 1994 Jan;43(1):80-6
pubmed: 8262321
Thyroid. 2010 Jul;20(7):777-83
pubmed: 20578901
N Engl J Med. 2016 Oct 20;375(16):1552-1565
pubmed: 27797318
Thyroid. 2009 Feb;19(2):99-102
pubmed: 19191741
Int J Gen Med. 2020 Oct 12;13:803-816
pubmed: 33116772
Diabetes Metab Syndr Obes. 2021 Mar 05;14:1025-1033
pubmed: 33707961
Diabetes. 1991 Mar;40(3):319-22
pubmed: 1999272
Thyroid. 2008 Sep;18(9):953-8
pubmed: 18713026
Thyroid. 2017 Jan;27(1):29-38
pubmed: 27809684
N Engl J Med. 2004 May 13;350(20):2068-79
pubmed: 15141045
Int J Health Policy Manag. 2020 Feb 01;9(2):47-52
pubmed: 32124588
Thyroid. 2018 Apr;28(4):528-536
pubmed: 29589999
Diabetes Care. 2010 Dec;33(12):2546-8
pubmed: 20823345
Eur Thyroid J. 2019 Apr;8(2):59-63
pubmed: 31192143
Diabetologia. 1981 Jun;20(6):602-6
pubmed: 7262475
Thyroid. 2014 Nov;24(11):1566-74
pubmed: 25069017
Indian J Endocrinol Metab. 2017 Jan-Feb;21(1):26-30
pubmed: 28217494
Diabetes Res Clin Pract. 2019 Nov;157:107843
pubmed: 31518657
Indian J Ophthalmol. 2020 Jun;68(6):1127-1131
pubmed: 32461446
Br J Ophthalmol. 1999 Apr;83(4):463-5
pubmed: 10434871
Metabolism. 1986 Apr;35(4):337-42
pubmed: 3515118
Diabetes. 2005 Dec;54 Suppl 2:S52-61
pubmed: 16306341
Ophthalmic Plast Reconstr Surg. 2021 Jul-Aug 01;37(4):352-360
pubmed: 33060509
Endocr Rev. 2019 Jun 1;40(3):789-824
pubmed: 30649221
Cell Metab. 2016 Jul 12;24(1):118-29
pubmed: 27411013
J Clin Endocrinol Metab. 2017 Feb 1;102(2):434-442
pubmed: 27906594
Diabet Med. 2014 Feb;31(2):126-35
pubmed: 24103027
Curr Med Sci. 2020 Feb;40(1):69-77
pubmed: 32166667
Pharmacol Ther. 2020 May;209:107502
pubmed: 32061922
Maedica (Bucur). 2020 Jun;15(2):169-173
pubmed: 32952680
Autoimmunity. 2018 Dec;51(8):408-416
pubmed: 30661481
Lancet. 1988 Nov 19;2(8621):1155-8
pubmed: 2903375
Nat Rev Endocrinol. 2020 Feb;16(2):104-116
pubmed: 31889140
Eur Thyroid J. 2016 Mar;5(1):9-26
pubmed: 27099835
N Engl J Med. 2010 Feb 25;362(8):726-38
pubmed: 20181974
Immunol Rev. 2012 Sep;249(1):239-52
pubmed: 22889226
Yonsei Med J. 2013 Jul;54(4):1033-9
pubmed: 23709442
J Endocrinol Invest. 2021 Mar;44(3):421-429
pubmed: 32729049
Endocrine. 2014 Feb;45(1):106-13
pubmed: 23572405
Front Endocrinol (Lausanne). 2019 Jan 17;9:810
pubmed: 30705666
Metabolism. 2011 Jun;60(6):761-6
pubmed: 20825955
J Clin Invest. 1976 Oct;58(4):820-4
pubmed: 965489
Diabetes Care. 2003 Apr;26(4):1181-5
pubmed: 12663594
Clin Endocrinol (Oxf). 2004 Nov;61(5):612-8
pubmed: 15521965
Diabetologia. 1985 Jul;28(7):412-9
pubmed: 3899825
Nat Rev Endocrinol. 2020 Mar;16(3):130-131
pubmed: 31907399
Thyroid. 2002 Oct;12(10):855-60
pubmed: 12487767
Diabetes Res Clin Pract. 1993 Aug-Sep;21(2-3):161-6
pubmed: 8269817
Nutr Metab Cardiovasc Dis. 2015 May;25(5):452-7
pubmed: 25746910
Diabet Med. 2002 Jul;19(7):527-34
pubmed: 12099954